This inventor holds 5 USPTO granted patents and 2 published patent applications, plus 3 CIPO patents and 3 EPO patents. Top assignees: The University of Texas System, Max-Delbrueck-Centrum Fuer Molekulare Medizin, Max-Delbruck-Centrum Fur Molekulare Medizin. Active years: 2016-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
4 out of 5,638 
3 out of 18 
1 out of 32 Years Active: 2016-2025
Title: Innovations of Wolf-Hagen Schunck: A Pioneer in Eicosanoid Research
Introduction
Wolf-Hagen Schunck, based in Berlin, Germany, is an influential inventor known for his significant contributions to the field of medicinal chemistry. With a total of five patents, his work primarily revolves around the development of novel compounds that address critical health issues related to neovascularization and inflammation.
Latest Patents
Among his latest innovations, Schunck has developed analogs of CYP-eicosanoids designed for treating or preventing disorders associated with neovascularization and inflammation. This invention focuses on compounds that are robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs). These compounds aim to treat or reduce the risk of developing inflammatory disorders, particularly those related to ophthalmic conditions. Furthermore, Schunck has introduced eicosanoid derivatives that modulate conditions associated with cardiac damage, especially cardiac arrhythmias.
Career Highlights
Wolf-Hagen Schunck has had a distinguished career, contributing to prestigious institutions such as the University of Texas System and Max-Dellbrueck-Centrum für Molekulare Medizin. His impressive expertise in the field has enabled him to explore innovative therapies, significantly impacting the understanding and treatment of various medical conditions.
Collaborations
Throughout his career, Schunck has collaborated with notable figures in the scientific community, including Robert Fischer and Gerd Wallukat. These partnerships have fostered a rich environment for innovation and the advancement of research in eicosanoid-related therapies.
Conclusion
In summary, Wolf-Hagen Schunck's groundbreaking work in developing eicosanoid analogs highlights his dedication to improving healthcare outcomes. His innovative patents serve as a testament to his commitment to addressing pressing health challenges through scientific discovery and collaboration.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile